Johnson & Johnson (JNJ) said to agree to $1 billion accord in Risperdal sales probe
Tweet
Share
E-mailGet Alerts JNJ Hot Sheet
Join SI Premium – FREE
Johnson & Johnson (NYSE: JNJ) said to agree to $1 billion accord in Risperdal sales probe.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
- BMO starts chip stocks coverage: Here are its preferred picks
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Create E-mail Alert Related Categories
FDA, General News, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
